Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Cyteir Therapeutics, Inc.
Cyteir Therapeutics, Inc. News
Mar 7, 2024 - businesswire.com
Cyteir Announces Timeline for Voluntarily Delisting from Nasdaq
Oct 12, 2023 - businesswire.com
Ongoing Results From a Dose Expansion Cohort of CYT-0851 in Combination With Capecitabine in Advanced Platinum-Resistant Ovarian Cancer Show Promising Clinical Activity and Generally Well Tolerated Safety Profile
Cyteir Therapeutics, Inc. Quantitative Score
About Cyteir Therapeutics, Inc.
Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the next-generation of precision oncology medicines. Its lead product CYT-0851, a novel, oral, once-daily, small molecule drug candidate that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies. The company is also developing CYT-1853, which is in preclinical trials for solid tumors and hematologic malignancies. The company was incorporated in 2012 and is based in Lexington, Massachusetts.
Cyteir Therapeutics, Inc. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Cyteir Therapeutics, Inc. Financials
Table Compare
Compare CYT metrics with: | |||
|---|---|---|---|
Earnings & Growth | CYT | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | CYT | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | CYT | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | CYT | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Cyteir Therapeutics, Inc. Income
Cyteir Therapeutics, Inc. Balance Sheet
Cyteir Therapeutics, Inc. Cash Flow
Cyteir Therapeutics, Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Buy |
| Return on Equity | Neutral |
| Return on Assets | Neutral |
| Debt/Equity Ratio | Sell |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Buy |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Cyteir Therapeutics, Inc. Dividends
| Yield (TTM) | Dividend (TTM) | |
|---|---|---|
Infinity% | 0.5200 |
| Payment Date | Dividend | Frequency |
|---|---|---|
| 2015-11-25 | 0.13 | Quarterly |
| 2015-08-25 | 0.13 | Quarterly |
| 2015-05-26 | 0.13 | Quarterly |
| 2015-02-25 | 0.13 | Quarterly |
| 2014-11-25 | 0.13 | Quarterly |
Historical Market Cap
Shares Outstanding
Cyteir Therapeutics, Inc. Executives
| Name | Role |
|---|---|
| Dr. Markus F. Renschler M.D. | President, Chief Executive Officer & Director |
| Mr. Joseph S. Zakrzewski | Independent Investor & Independent Chairman of the Board |
| Mr. David G. Gaiero | Chief Financial Officer & Treasurer |
| Dr. Kevin Mills Ph.D. | Co-Founder |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Dr. Markus F. Renschler M.D. | President, Chief Executive Officer & Director | 1961 | 718.62K | |
| Mr. Joseph S. Zakrzewski | Independent Investor & Independent Chairman of the Board | Male | 1962 | 81.5K |
| Mr. David G. Gaiero | Chief Financial Officer & Treasurer | Male | 1978 | -- |
| Dr. Kevin Mills Ph.D. | Co-Founder | -- |
Cyteir Therapeutics, Inc. Insider Trades
| Date | 20 Mar |
| Name | Leonard Braden Michael |
| Role | 10 percent owner |
| Transaction | Acquired |
| Type | P-Purchase |
| Shares | 170589 |
| Date | 18 Mar |
| Name | Leonard Braden Michael |
| Role | 10 percent owner |
| Transaction | Acquired |
| Type | P-Purchase |
| Shares | 113777 |
| Date | 15 Mar |
| Name | Leonard Braden Michael |
| Role | 10 percent owner |
| Transaction | Disposed |
| Type | |
| Shares | 0 |
| Date | 15 Mar |
| Name | Leonard Braden Michael |
| Role | 10 percent owner |
| Transaction | Disposed |
| Type | |
| Shares | 0 |
| Date | 29 Feb |
| Name | Gaiero David G |
| Role | Chief Financial Officer |
| Transaction | Acquired |
| Type | M-Exempt |
| Shares | 3239 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 20 Mar | Leonard Braden Michael | 10 percent owner | Acquired | P-Purchase | 170589 |
| 18 Mar | Leonard Braden Michael | 10 percent owner | Acquired | P-Purchase | 113777 |
| 15 Mar | Leonard Braden Michael | 10 percent owner | Disposed | 0 | |
| 15 Mar | Leonard Braden Michael | 10 percent owner | Disposed | 0 | |
| 29 Feb | Gaiero David G | Chief Financial Officer | Acquired | M-Exempt | 3239 |